Cocrystal Pharma, Inc. (NASDAQ:COCP) Sees Significant Increase in Short Interest

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 202,066 shares, a growth of 26.0% from the January 15th total of 160,347 shares. Approximately 2.0% of the shares of the stock are sold short. Based on an average daily volume of 66,811 shares, the days-to-cover ratio is currently 3.0 days. Based on an average daily volume of 66,811 shares, the days-to-cover ratio is currently 3.0 days. Approximately 2.0% of the shares of the stock are sold short.

Cocrystal Pharma Price Performance

Shares of COCP stock opened at $0.96 on Tuesday. The business has a 50-day moving average of $1.02 and a 200 day moving average of $1.18. Cocrystal Pharma has a 1-year low of $0.86 and a 1-year high of $2.67. The stock has a market capitalization of $13.30 million, a PE ratio of -1.03 and a beta of 1.20.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.03. Analysts anticipate that Cocrystal Pharma will post -1.85 EPS for the current year.

Insider Buying and Selling at Cocrystal Pharma

In other news, Director Phillip Md Et Al Frost bought 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was bought at an average price of $0.95 per share, for a total transaction of $47,500.00. Following the transaction, the director directly owned 1,888,551 shares of the company’s stock, valued at $1,794,123.45. This represents a 2.72% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders bought 209,000 shares of company stock worth $200,210. Company insiders own 28.14% of the company’s stock.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC acquired a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma at the end of the most recent quarter. 6.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.